[Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].

Abstract

In a single-blind trial 25 patients with progressive scleroderma and Raynaud's phenomenon intravenous infusions of iloprost, a prostacyclin derivative (carbaprostacyclin), were given daily for five hours during a six-day hospital stay, after a comparable initial single placebo infusion. Duration, frequency and intensity of Raynaud symptoms improved in more than 75% of the patients. This improvement was objectified by telethermometry which demonstrated acral hyperthermia and significantly briefer rewarming after standardized cooling of the hands. In addition, there was more rapid healing of ulcerations and necroses of the digital pulp. A significant inhibition of ADP- and collagen-dependent platelet aggregation was demonstrated during the iloprost infusion. Side effects, such as headache, nausea and tiredness occurred only transitorily during the infusion, were individually highly variable, and then only at higher concentrations. A dosage of 2 ng/kg X min was tolerated by all patients.

• Authors: J Keller, A Kaltenecker, K T Schricker, T Krais, A Schönberger, M Gevatter, O P Hornstein
• Journal: Deutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 109 Issue 38 Pg. 1433-8 (Sep 21 1984) ISSN: 0012-0472 [Print] Germany
• Vernacular Title: Behandlung des Raynaud-Phänomens bei Sklerodermie-Patienten mit einem neuen stabilen Prostacyclin-Derivat.
• PMID: 6383760 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• carboprostacyclin
• Epoprostenol

Topics

• Adult
• Aged
• Epoprostenol (adverse effects, analogs & derivatives, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Raynaud Disease (drug therapy, etiology)
• Scleroderma, Systemic (complications)